463303-98-2

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-4-pyridinepropanoic acid ethyl ester is used as a building block for the synthesis of various pharmaceuticals due to its unique chemical properties and potential therapeutic applications.
Used in Agrochemical Industry:
3-Bomo-4-pridinepropanoic acidethylester is also utilized as a precursor in the development of agrochemicals, contributing to the creation of effective solutions for agricultural challenges.
Used in Erectile Dysfunction Treatment:
3-Bromo-4-pyridinepropanoic acid ethyl ester is used as a potential therapeutic agent for the treatment of erectile dysfunction, leveraging its ability to inhibit the enzyme cGMP-specific phosphodiesterase type 5, which plays a crucial role in this condition.
Used in Synthesis of Biologically Active Compounds:
As a reagent, 3-Bromo-4-pyridinepropanoic acid ethyl ester is employed in the synthesis of biologically active compounds, facilitating the development of new drugs and therapeutic agents.
Used in Medicinal Chemistry and Drug Discovery:
This chemical compound is used as a key component in research and development within the fields of medicinal chemistry and drug discovery, driving innovation and the advancement of novel treatments.

Upstream product

• 6414-69-3 ethyl 3-iodopropanoate 
• 92915-13-4 3-bromopyridinium ethylformate chloride 
• 626-55-1 3-Bromopyridine 
• 105-36-2 ethyl bromoacetate 
• 3430-22-6 3-Bromo-4-methylpyridin 

Relevant academic research and scientific papers

Conformationally constrained nicotines: Polycyclic, bridged, and spiro-annulated analogues as novel ligands for the nicotinic acetylcholine receptor

A set of novel nicotine-related, conformationally constrained compounds, including tetracyclic, bridged (4), and tricyclic, spiro-annulated (5) structures, were synthesized in a straightforward manner and optically resolved in a convenient fashion with (+)- and (-)-O,O′-di-p-toluoyltartaric acids. Absolute configurations were determined by X-ray crystallography. These compounds were evaluated for their ability to displace [3H]cytisine in a rat forebrain preparation and compared to (-)-nicotine. Three substances emerged With high affinity in the low nanomolar range. Moreover, one of these compounds ((+)-5b) showed not only high binding affinity (Ki = 4.79 nM) but also significant enantioselectivity over its antipode (Ki = 148 nM), supporting the hypothesis that conformational restraint can lead to high-affinity ligands, which are stereochemically discriminated by the nicotinic acetylcholine receptor and may feature optimum locations of the active sites of the pharmacophore.

Carboxylic acid compound and preparation method and use thereof

The present invention relates to the technical field of medicines, and particularly relates to a carboxylic acid compound shown as a chemical formula I or formula II, a pharmaceutically acceptable salt, a prodrug, a solvate and a preparing method thereof,